Jocasta and Diamond launch joint research on non-hallucinogenic psychedelic-inspired compounds

Jocasta Neuroscience and Diamond Therapeutics have entered a joint research agreement to test three compounds aimed at cognitive impairment and neurodegeneration. The program could lead to an exclusive license for Jocasta and comes as the company prepares first-in-human trials for its lead asset in early 2027.

Why it matters: - The collaboration targets cognitive impairment and neurodegeneration, two areas where many patients still lack effective treatment options. - The program aims to preserve the cognitive benefits associated with psychedelic-based medicine while avoiding hallucinogenic side effects that have limited broader use. - Jocasta’s lead asset, JN-0413, is already headed toward first-in-human clinical trials at the start of 2027, giving the company a second pipeline path in cognitive decline.

What happened: - Jocasta Neuroscience and Diamond Therapeutics entered into a joint research agreement focused on cognitive impairment and neurodegeneration. - Jocasta will evaluate three new chemical entities discovered by Diamond Therapeutics. - The companies announced the agreement on Oct. 13, 2026, in Toronto. - Jocasta will fund the joint research program. - Jocasta will make an upfront payment to Diamond Therapeutics through a convertible debenture exchangeable into Diamond’s preferred shares.

The details: - The three compounds are designed to mimic psilocybin’s receptor occupancy pattern while avoiding activity tied to hallucinogenic effects. - The research program will test the compounds in preclinical studies for pharmacokinetics, behavioral effects and cognitive performance. - Compounds that improve cognitive performance without hallucinogenic-like effects will move forward for further development. - If the program is successful, Jocasta can obtain an exclusive, royalty-bearing license to research, develop, manufacture and commercialize the compounds. - The license would also include downstream development and commercial milestone payments to Diamond Therapeutics, plus tiered royalties on net sales. - Further financial terms were not disclosed. - Jocasta’s lead asset, JN-0413, is an α-klotho-based therapeutic candidate for cognitive decline in neurodegenerative disease. - JN-0413 is set to begin first-in-human clinical trials at the start of 2027. - Diamond Therapeutics is a Toronto- and Birmingham, Alabama-based clinical-stage drug development company focused on rapid-acting behavioral and mental health therapeutics. - Diamond Therapeutics’ platform includes 5-HT receptor agonists such as psilocybin and other novel neuroplastogens.

Between the lines: - The deal gives Jocasta access to compounds aimed at separating therapeutic signaling from hallucinogenic side effects, a major hurdle for psychedelic-derived drugs. - The companies are betting that selective targeting of downstream signaling pathways can improve cognitive function without the safety and tolerability tradeoffs seen in earlier approaches. - Diamond Therapeutics framed the partnership as a way to extend its neuroplastic molecules into cognitive impairment and neurodegenerative disease.

What's next: - The joint research team will begin preclinical testing on the three compounds. - Jocasta will decide later whether to exercise its option for the exclusive license. - JN-0413 is expected to advance into clinical trials in early 2027. - The companies said the research program could support future development if the compounds show cognitive benefits without hallucinogenic-like effects.

The bottom line: - Jocasta is broadening its neurodegeneration pipeline with a bet that psychedelic-inspired chemistry can deliver cognitive benefits without the hallucinogenic baggage.